Breast cancer in young women and prognosis: How important are proliferation markers?. (October 2017)

• Record Type: Journal Article
• Authors: Fredholm, Hanna; Magnusson, Kristina; Lindström, Linda S.; Tobin, Nicholas P.; Lindman, Henrik; Bergh, Jonas; Holmberg, Lars; Pontén, Fredrik; Frisell, Jan; Fredriksson, Irma
• Is Part Of: European journal of cancer. Volume 84(2017)
• Page Start: 278
• Page End: 289
• Publication Date: 2017-10
• Subjects: Breast cancer -- Young -- Age -- Subtype -- Luminal -- Progesterone receptor -- Ki-67 -- Cyclin -- Prognosis -- Population-based; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2017.07.044
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Aim: Compared to middle-aged women, young women with breast cancer have a higher risk of systemic disease. We studied expression of proliferation markers in relation to age and subtype and their association with long-term prognosis. Methods: Distant disease-free survival (DDFS) was studied in 504 women aged <40 years and 383 women aged ≥40 years from a population-based cohort. Information on patient characteristics, treatment and follow-up was collected from medical records. Tissue microarrays were produced for analysis of oestrogen receptor, progesterone receptor (PR), Her2, Ki-67 and cyclins. Results: Young women with luminal tumours had significantly higher expression of Ki-67 and cyclins. Proliferation markers were prognostic only within this subtype. Ki-67 was a prognostic indicator only in young women with luminal PR+ tumours. The optimal cut-off for Ki-67 varied by age. High expression of cyclin E1 conferred a better DDFS in women aged <40 years with luminal PR− tumours (hazard ratio [HR] 0.47 [0.24–0.92]). Age <40 years was an independent risk factor of DDFS exclusively in women with luminal B PR+ tumours (HR 2.35 [1.22–4.50]). Young women with luminal B PR− tumours expressing low cyclin E1 had a six-fold risk of distant disease compared with luminal A (HR 6.21 [2.17–17.6]). Conclusions: The higher expression of proliferation markers in young women does not have a strong impact on prognosis. Ki-67 is only prognostic in the subgroup of young women with luminal PR+ tumours. The only cyclin adding prognostic value beyond subtype is cyclin E1. Age is an independent prognostic factor only in women with luminal B PR+ tumours. Highlights: Proliferation markers are highly expressed in young women with breast cancer. Proliferation markers do not have a major prognostic impact in young women. Ki-67 is only prognostic in young women with luminal progesterone receptor–positive (PR+) tumours. The optimal prognostic cut-off for Ki-67 varies by age. Age is an independent prognostic factor only in women with luminal B PR+ tumours.